| Just Answers |
Hubs | Hubbers | Topics | Request |
| #1 in Business | Subscribe Email Print |
|
You are here: Home > Finance > Investing > Price To Earnings Ratio |
|
Just Answers - Price To Earnings Ratio
This ratio represents how much the stock costs versus how much money the compa According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product ny is making. Because you know much investors are willing to pay for a stock b ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug. Examples of combination products may in ased on its earnings, you can learn how much growth people expect from this st lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together. ock. Effectively it tells you if the stock is cheap, too expensive, or just ab here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe out fair value, and therefore whether it is more likely appreciate or deprecia d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations. Combination pro te. You should generally look for companies with low P/E ratios. During the d ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc ot-com bubble, many companies achieved outrageous P/E ratios because people ha easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi d wild expectations for the success of these companies and purchased their sto nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically ck willy-nilly. People began to think that P/E ratio was irrelevant, and that and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ the stock market had infinite upward momentum. After the bubble, P/E ratio is ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi again in vogue. When looking for a stock, you should compare the P/E ratio of ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it. Following aspects would a a company to other companies in its sector. It is useless to compare ratios ac dd to the challenges in developing combination products: Which markets to tap where the combination products can do fairly well? Which combination prod ross industries because the dynamics of different industries can vary widely. cts are meaningful and rational? Which therapeutic categories to select? Which Combinations can address unmet needs of the patients? Do combin It is not totally unadvisable to purchase companies that are not profitable an tions increase the patient compliance? What would be the developing cost? How to tackle the risks encountered during combination product developmen d therefore have no P/E ratio. These companies represent higher risk investmen t? As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel ts. It is also important to note that P/E ratios are based an accounting meas ping new procedures for reviewing their safety, efficacy and quality. Professional from academic institutions, pharmaceutical industries, health care indust ure of earnings, and that means they are subject to tinkering and clever manip y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products ulation. One should look at many other factors when picking a stock. P/E ratio . As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de is just one measure of a company's health and prospects for future success. C elopment. They need to be wiser in analyzing the market trends and the regulatory requirements. Companies that provide selfless information through particip ompanies that are profitable have stocks with P/E, or Price to Earnings ratios tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products
HTTP = HTML link (for blogs, profiles,phorums):
Related Articles:Business Ethics: The Law of Corporate Karma Earn A Solid Income From Bad Dogs Audio Books Can Add Revenue And Unique Content To Your Site
|